Can I Take St. John's Wort with TB-500?

What Is TB-500 and Why Are Women Using It?

TB-500 is a synthetic peptide fragment of thymosin beta-4, a naturally occurring protein found in nearly every human tissue. The full-length thymosin beta-4 peptide was first isolated from bovine thymus tissue in the 1960s, and TB-500 represents the four-to-nine amino-acid active segment responsible for much of the protein's tissue-repair signaling. It is not FDA-approved for clinical use in humans but is available through 503A compounding pharmacies for individualized patient prescriptions.

Women are increasingly seeking TB-500 for a range of off-label purposes. These include accelerated recovery from musculoskeletal injuries, reduced inflammation in conditions like endometriosis-adjacent pelvic pain, and improved tissue healing after surgery. None of these indications have been validated in large randomized controlled trials in women.

How TB-500 Is Thought to Work

Thymosin beta-4 promotes cell migration, angiogenesis, and modulation of the actin cytoskeleton. In preclinical models, it has demonstrated anti-inflammatory effects through downregulation of NF-kB signaling pathways. A 2010 study published in Annals of the New York Academy of Sciences via PubMed outlined its role in wound healing and cardiac repair in animal models. Human data remain sparse. The peptide is typically administered by subcutaneous injection, with common research protocols using doses between 2 mg and 5 mg two to three times per week, though no standardized human dosing has been established by any regulatory body.

The Evidence Gap for Women Specifically

Women have been systematically underrepresented in peptide research. Almost all published thymosin beta-4 data come from male animal models or mixed-sex cell-culture experiments. This means that how the female hormonal milieu, including estrogen fluctuations across the menstrual cycle or the sharp estrogen decline of menopause, affects TB-500 bioavailability, tissue distribution, or effect duration is entirely unknown. Treat any claim about TB-500 efficacy in women as extrapolated, not directly studied.

What Is St. John's Wort and What Does It Do to Your Body's Enzymes?

St. John's Wort (Hypericum perforatum) is an herbal supplement with a long history of use for mild-to-moderate depression, anxiety, and, increasingly, perimenopausal mood changes. It contains two primary active constituents: hypericin and hyperforin. Hyperforin is the compound responsible for most of the drug-interaction risk.

St. John's Wort is one of the most potent known inducers of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) efflux transport. A landmark 2000 study in The Lancet documented a 57% reduction in cyclosporine blood levels in organ-transplant patients who started taking St. John's Wort, leading to acute rejection episodes in two patients. The FDA issued a public health advisory about these interactions that same year, accessible via FDA's archived safety communications.

CYP3A4 Induction: What It Means in Plain Language

CYP3A4 is the liver enzyme responsible for metabolizing roughly 50% of all prescription drugs and many endogenous hormones, including estradiol. When St. John's Wort upregulates this enzyme, it accelerates the breakdown of any substance that CYP3A4 normally processes. The result is lower-than-expected blood concentrations of the co-administered compound. For a drug with a narrow therapeutic window, this can mean treatment failure or, in some cases, rebound of a condition that was previously controlled.

What About P-glycoprotein?

P-gp is an intestinal efflux pump that limits how much of a substance crosses from the gut into systemic circulation. St. John's Wort induces P-gp alongside CYP3A4, creating a double-barrier effect that further reduces the bioavailability of co-administered substances. This induction takes approximately 7-14 days to reach its maximum effect and persists for roughly 1-2 weeks after stopping the herb.

Does St. John's Wort Actually Interact with TB-500?

This is where honest clinical reasoning matters more than confident-sounding claims.

TB-500 is a peptide, meaning it is a short chain of amino acids. Peptides are not typically metabolized by CYP3A4 in the same way small-molecule drugs are. Small molecules are lipophilic and enter hepatocytes for enzymatic processing. Peptides are generally broken down by proteases in the bloodstream, kidneys, and intestinal lining rather than by cytochrome P450 enzymes in the liver. So a direct pharmacokinetic interaction via CYP3A4 between St. John's Wort and TB-500 is not a well-established pathway and is likely low probability based on pharmacological class alone.

This distinction matters because most online sources either overstate the interaction (applying all CYP3A4 warnings blanket-style to TB-500) or dismiss it entirely. The accurate answer sits in the middle:

Direct pharmacokinetic interaction (St. John's Wort inducing TB-500 metabolism via CYP3A4): Unlikely. TB-500 is a peptide and does not follow the hepatic CYP450 metabolic pathway that governs small molecules.

Indirect pharmacodynamic interaction (both substances affecting the same downstream systems in ways that compound or conflict): Plausible but unstudied. Both have reported effects on inflammation and immune signaling. Thymosin beta-4 modulates NF-kB and actin dynamics. Hyperforin in St. John's Wort has demonstrated anti-inflammatory effects in preclinical models, though a 2017 review in Frontiers of Pharmacology indexed on PubMed concluded that its mechanisms differ substantially from those of TB-500's peptide fragments. Whether layering these effects is additive, neutral, or occasionally counterproductive in humans is unknown.

The real risk for most women using this combination: St. John's Wort will interact with the OTHER medications they are taking alongside TB-500, not with TB-500 itself. This is the clinically significant concern.

The Interactions That Actually Put Women at Risk

If you are taking TB-500, you are almost certainly also taking other compounds. Most women using peptides for recovery or anti-inflammatory purposes are not taking TB-500 in isolation. The St. John's Wort risk to you is about what else is in your stack, your prescription list, or your hormonal health regimen.

Hormonal Contraception

This is the highest-priority concern for women of reproductive age. St. John's Wort reduces the plasma concentration of ethinyl estradiol and progestins in combined oral contraceptives via CYP3A4 and P-gp induction. A study published in Contraception via PubMed documented breakthrough bleeding and reduced levonorgestrel bioavailability in women taking St. John's Wort alongside low-dose OCs. The UK's MHRA and the UK Faculty of Sexual and Reproductive Healthcare explicitly list St. John's Wort as an enzyme-inducing drug that requires barrier contraception backup or switching to a non-hormonal method.

If you are using TB-500 during reproductive years and relying on a combined OCP for contraception, adding St. John's Wort without a backup method is not a safe choice.

Antidepressants and Serotonin Syndrome

Women are diagnosed with depression at approximately twice the rate of men, and antidepressant use is common across reproductive and perimenopausal years. St. John's Wort has serotonergic activity of its own. A systematic review in BMJ confirmed its efficacy for mild-to-moderate depression while also documenting serotonin syndrome cases when combined with SSRIs. If your TB-500 protocol overlaps with an SSRI or SNRI prescription, St. John's Wort is contraindicated without psychiatric supervision.

Hormone Replacement Therapy in Perimenopause and Menopause

For women in perimenopause or post-menopause using estradiol patches, pills, or sprays alongside progestins, St. John's Wort may reduce circulating estradiol levels through CYP3A4 induction. The Menopause Society (formerly NAMS) notes that herbal supplements with enzyme-inducing properties can compromise HRT efficacy. A woman managing vasomotor symptoms who adds St. John's Wort may see a return of hot flashes because her estradiol exposure has dropped, not because her HRT dose was wrong.

Thyroid Medications

Postpartum thyroiditis and Hashimoto's thyroiditis are common in women. Levothyroxine, the standard treatment, is a P-gp substrate. St. John's Wort-mediated P-gp induction can reduce levothyroxine absorption from the gut. A case report in Drug Metabolism and Pharmacokinetics indexed on PubMed documented elevated TSH in a patient after starting St. John's Wort with no dose change to levothyroxine. If you are on thyroid medication, tell your prescriber before adding St. John's Wort to any supplement regimen.

Pregnancy, Lactation, and Contraception: What You Must Know

TB-500 is not established as safe in human pregnancy. Full stop.

No controlled human trials exist. Animal reproductive toxicology data for TB-500 specifically are not publicly available in peer-reviewed literature as of the date of this article. Given that thymosin beta-4 has roles in embryonic development, cardiac morphogenesis, and immune programming, there is a biologically plausible concern about exogenous supplementation during organogenesis. ACOG's framework for evaluating unproven therapies in pregnancy advises against any compound without adequate human safety data during pregnancy.

Do not use TB-500 if you are pregnant or trying to conceive, unless a reproductive endocrinologist has reviewed your specific situation and explicitly approved use.

St. John's Wort in Pregnancy

St. John's Wort does cross the placenta. A PubMed-indexed study in Pharmacoepidemiology and Drug Safety found hyperforin in cord blood samples. While no large registry study has conclusively linked St. John's Wort to congenital anomalies, insufficient data exist to call it safe. ACOG advises against most herbal supplements during the first trimester when organogenesis is most sensitive.

Lactation

Hypericin, the primary constituent of St. John's Wort, has been detected in breast milk. A small study in Breastfeeding Medicine indexed on PubMed found measurable hypericin in the breast milk of three women taking St. John's Wort, with infant plasma levels detectable in one infant. Drowsiness was reported in one infant. The LactMed database classifies St. John's Wort as potentially problematic in lactation, and its use is generally not recommended during breastfeeding without pediatric guidance.

TB-500 transfer into breast milk has not been studied. Because it is a peptide, some degree of proteolytic degradation in the infant gut is likely, but systemic exposure in newborns cannot be ruled out. Avoid both compounds during breastfeeding unless a clinician with lactation expertise has reviewed your case.

Contraception Requirements

If you are of reproductive age and using TB-500, you should be using effective non-hormonal contraception or a highly reliable long-acting reversible contraceptive (LARC) such as a copper IUD. Combined hormonal contraceptives that rely on CYP3A4-metabolized steroids will have reduced efficacy if you add St. John's Wort. The CDC's Medical Eligibility Criteria for Contraceptive Use classifies enzyme-inducing herbal products like St. John's Wort as a category that requires contraceptive counseling and potential method change.

Who Should Not Combine These Two Substances

Women for Whom This Combination Carries Clear Risk

• Women using combined oral contraceptives or progestin-only pills as their primary contraception
• Women on SSRIs, SNRIs, or any serotonergic medication
• Women on HRT (oral or transdermal estradiol plus progestins) for perimenopausal or menopausal symptoms
• Women on levothyroxine or other thyroid medications
• Women who are pregnant or actively trying to conceive
• Women who are breastfeeding
• Women on immunosuppressants (tacrolimus, cyclosporine), anticoagulants (warfarin), or antiretroviral medications, all of which have established serious interactions with St. John's Wort

Women for Whom the Direct TB-500 / St. John's Wort Interaction Risk Is Lower

Women who are not on any of the above medications or hormonal therapies face a lower direct interaction risk, given the pharmacokinetic argument that TB-500 as a peptide is unlikely to be significantly affected by CYP3A4 induction. The caution shifts to ensuring no other compounds in their regimen are affected.

What to Do If You Are Already Taking Both

First, do not stop either substance abruptly without guidance. Abrupt discontinuation of St. John's Wort can cause a rapid return of CYP3A4 to baseline, which can transiently increase blood levels of any substrate drugs back toward baseline or above, creating a different kind of instability.

Follow these practical steps:

1. Make a full medication and supplement list including doses, timing, and how long you have been taking each compound.
2. Book a telehealth or in-person appointment with the prescriber who initiated your TB-500 protocol. Most legitimate 503A compounding prescriptions involve a supervising clinician.
3. Request a pharmacist interaction review. Clinical pharmacists have access to Natural Medicines Database and Lexicomp and can run a full interaction screen across your entire list.
4. If you are on hormonal contraception, use a barrier method immediately until you can clarify whether your OCP efficacy is compromised.
5. Monitor symptoms including breakthrough bleeding (OCP users), return of hot flashes (HRT users), mood changes (antidepressant users), fatigue or cold intolerance (thyroid medication users), and any unexpected change in healing if you are using TB-500 for tissue repair.

Life-Stage Summary: TB-500 and St. John's Wort by Reproductive Phase

| Life Stage | Key Concern | |---|---| | Reproductive years (cycling) | OCP failure risk from St. John's Wort; TB-500 contraindicated in pregnancy | | Trying to conceive | Avoid both; TB-500 has no reproductive safety data | | Pregnant | Contraindicated; avoid both compounds | | Postpartum and lactating | Avoid both; infant exposure via breast milk not adequately studied | | Perimenopause | St. John's Wort may reduce HRT efficacy; monitor symptom return | | Post-menopause | Lower hormonal contraception concern; HRT interaction still applies; drug-interaction screen still needed |

Monitoring: What Tests Should You Ask For?

If a clinician has approved your use of TB-500 and you want to assess whether St. John's Wort is affecting anything in your hormonal or metabolic profile, these are the tests worth discussing:

• Estradiol and FSH (if on HRT or oral contraceptives) to assess whether circulating hormone levels remain in the therapeutic range
• TSH and free T4 (if on levothyroxine) every 6-8 weeks when adding or removing enzyme inducers
• CBC and CMP as a general safety baseline for any off-label peptide protocol
• Specific trough drug levels if you are on a narrow-therapeutic-index drug like tacrolimus or warfarin

The American Association of Clinical Endocrinology guidelines on thyroid monitoring recommend TSH reassessment 4-8 weeks after any change in co-administered drugs that affect levothyroxine absorption.

A Note on the Evidence Base for TB-500 Itself

Women deserve to know exactly how preliminary the TB-500 evidence is before making decisions. As of 2025, no completed phase II or phase III clinical trial in humans has been published specifically for TB-500 (thymosin beta-4 active fragment). The existing published work includes phase I cardiac trials of the full-length thymosin beta-4 in post-myocardial infarction patients, summarized in a 2010 paper in the Journal of the American College of Cardiology via PubMed, not in the truncated active-fragment form called TB-500. The animal data are genuinely interesting. The human extrapolation is exactly that: extrapolation.

When your prescriber or an online seller talks about TB-500 as a proven tissue-repair therapy, ask them to show you the phase II human trial. It does not yet exist. That does not mean the compound has no future, but it means you are participating in early-stage human experience, not established clinical practice.

FAQs